Article Information
History
- September 9, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Hui Gao1,*,
- Shibo Liu2,*,
- Yuanbang Mai3,
- Yuying Wang4,
- Xue-wu Zhang5,
- Shufen Zheng3,
- Chenghua Luo2,# and
- Cuiping Pan3,#
- 1Department of Rheumatology and Immunology, Peking University International Hospital, Beijing, China
- 2Department of retroperitoneal tumor surgery,Peking University International Hospital, Beijing, China
- 3Center for Intelligent Medicine Research, Greater Bay Area Institute of Precision Medicine (Guangzhou), School of Life Sciences, Fudan University. Guangzhou, China
- 4Department of Pharmacy, Peking University International Hospital, Beijing, China
- 5Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China
- ↵#Correspondence:
Chenghua Luo: luochenghua{at}pkuih.edu.cn, Cuiping Pan: pancuiping{at}ipm-gba.org.cn
↵* These authors contributed equally to this work.
Posted September 09, 2022.
Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis
